These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

485 related articles for article (PubMed ID: 27169615)

  • 61. Safety and Efficacy of Brentuximab Vedotin in the Treatment of Classic Hodgkin Lymphoma.
    Makita S; Maruyama D; Tobinai K
    Onco Targets Ther; 2020; 13():5993-6009. PubMed ID: 32606807
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Brentuximab vedotin therapy for CD30-positive cutaneous T-cell lymphoma: a targeted approach to management.
    Scarisbrick JJ
    Future Oncol; 2017 Nov; 13(27):2405-2411. PubMed ID: 28805086
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A phase 2 study of brentuximab vedotin in patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas: interim results in patients with DLBCL and other B-cell lymphomas.
    Clin Adv Hematol Oncol; 2014 Feb; 12(2 Suppl 6):3-4. PubMed ID: 24870871
    [No Abstract]   [Full Text] [Related]  

  • 64. Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma.
    Ward JP; Berrien-Elliott MM; Gomez F; Luo J; Becker-Hapak M; Cashen AF; Wagner-Johnston ND; Maddocks K; Mosior M; Foster M; Krysiak K; Schmidt A; Skidmore ZL; Desai S; Watkins MP; Fischer A; Griffith M; Griffith OL; Fehniger TA; Bartlett NL
    Blood; 2022 Mar; 139(13):1999-2010. PubMed ID: 34780623
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma.
    Vaklavas C; Forero-Torres A
    Ther Adv Hematol; 2012 Aug; 3(4):209-25. PubMed ID: 23606932
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Efficacy of antibody-drug conjugate brentuximab vedotin in treating Hodgkin's lymphoma.
    Viviani S; Guidetti A
    Expert Opin Biol Ther; 2018 Aug; 18(8):841-849. PubMed ID: 29999431
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Complete response to brentuximab vedotin in a transplant-naïve patient with relapsed CD30-positive nodular lymphocyte-predominant Hodgkin lymphoma.
    O'Sullivan CC; Ozdemirli M; Bazylewicz M; Cheson BD
    Clin Adv Hematol Oncol; 2013 Jun; 11(6):382-5. PubMed ID: 24472809
    [No Abstract]   [Full Text] [Related]  

  • 68. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma: An updated review of published data from the named patient program.
    Zinzani PL; Sasse S; Radford J; Gautam A; Bonthapally V
    Crit Rev Oncol Hematol; 2016 Aug; 104():65-70. PubMed ID: 27279289
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A20 and RBX1 Regulate Brentuximab Vedotin Sensitivity in Hodgkin Lymphoma Models.
    Wei W; Lin Y; Song Z; Xiao W; Chen L; Yin J; Zhou Y; Barta SK; Petrus M; Waldmann TA; Yang Y
    Clin Cancer Res; 2020 Aug; 26(15):4093-4106. PubMed ID: 32299816
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Treatment of CD30-Expressing Germ Cell Tumors and Sex Cord Stromal Tumors with Brentuximab Vedotin: Identification and Report of Seven Cases.
    Albany C; Einhorn L; Garbo L; Boyd T; Josephson N; Feldman DR
    Oncologist; 2018 Mar; 23(3):316-323. PubMed ID: 29222199
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Durable remission attained by long-term brentuximab vedotin administration in a relapsed post-allogeneic bone marrow transplant Hodgkin lymphoma patient].
    Ono Y; Hiramoto N; Yoshioka S; Yabushita T; Koba Y; Tabata S; Imai Y; Ishikawa T
    Rinsho Ketsueki; 2017; 58(12):2397-2401. PubMed ID: 29332873
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma.
    Siddiqi T; Thomas SH; Chen R
    Pharmgenomics Pers Med; 2014; 7():79-85. PubMed ID: 24672256
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Immuno-PET Imaging of CD30-Positive Lymphoma Using 89Zr-Desferrioxamine-Labeled CD30-Specific AC-10 Antibody.
    Rylova SN; Del Pozzo L; Klingeberg C; Tönnesmann R; Illert AL; Meyer PT; Maecke HR; Holland JP
    J Nucl Med; 2016 Jan; 57(1):96-102. PubMed ID: 26514172
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Brentuximab vedotin in systemic T-cell lymphoma.
    Oki Y; Younes A
    Expert Opin Biol Ther; 2012 May; 12(5):623-32. PubMed ID: 22428917
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30-positive aggressive lymphomas.
    Wagner SM; Melchardt T; Egle A; Magnes T; Skrabs C; Staber P; Simonitsch-Klupp I; Panny M; Lehner B; Greil R; Keil F; Jäger U; Sillaber C
    Eur J Haematol; 2020 Mar; 104(3):251-258. PubMed ID: 31838747
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma.
    Jagadeesh D; Horwitz S; Bartlett NL; Kim Y; Jacobsen E; Duvic M; Little M; Trepicchio W; Fenton K; Onsum M; Lisano J; Advani R
    Oncologist; 2022 Oct; 27(10):864-873. PubMed ID: 35948003
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Could bystander killing contribute significantly to the antitumor activity of brentuximab vedotin given with standard first-line chemotherapy for Hodgkin lymphoma?
    Brown MP; Staudacher AH
    Immunotherapy; 2014; 6(4):371-5. PubMed ID: 24815777
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Sequencing novel agents in the treatment of classical Hodgkin lymphoma.
    Ferhanoglu B; Ozbalak M
    Expert Rev Hematol; 2023; 16(12):991-1015. PubMed ID: 37897182
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Hodgkin lymphoma].
    Nagai H
    Nihon Rinsho; 2014 Jun; 72(6):1099-103. PubMed ID: 25016811
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma.
    Wang Y; Nowakowski GS; Wang ML; Ansell SM
    J Hematol Oncol; 2018 Apr; 11(1):57. PubMed ID: 29685160
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.